AAPG

Neutral

Ascentage Pharma Showcases Promising Combination Oncology Data at AACR 2026

Ascentage Pharma will present preclinical data for its key drug candidates olverembatinib, APG-2449, and APG-5918 at the AACR 2026 Annual Meeting. The...

TipRanks 1 hour ago 0

Bullish

Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting

Ascentage Pharma announced it will present four preclinical studies at the AACR 2026 Annual Meeting, highlighting new combination therapy potentials f...

Carroll County Mirror-Democrat 1 hour ago 0

Bullish

Leukemia drug tested beyond CML in 4 cancer combination studies

Ascentage Pharma announced it will present four preclinical studies at the AACR 2026 Annual Meeting, highlighting the potential of combination therapi...

Stock Titan 1 hour ago 0